<div id="readability-page-1">New insider activity at NeOnc Technologies Holdings, Inc. ( (NTHI) ) has taken place on May 4, 2026.<h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul> NeOnc Technologies Holdings, Inc. has seen a notable insider purchase as President Amir F. Heshmatpour acquired 10,000 shares of the company’s stock in a recent transaction. The total value of this buy amounts to $41,500, signaling a meaningful show of confidence from the company’s top leadership in NeOnc’s future prospects. Recent Updates on NTHI stock In the last day, NeOnc drew attention as analysts framed price targets around two main forces: aggressive capital-raising and advancing CNS oncology programs. Targets cited the company’s new ATM equity facility, recent private placements, and a resale filing as both dilution risks and liquidity support, weighed against early efficacy data and upcoming readouts for NEO100 and NEO212 in hard-to-treat brain tumors. Spark’s Take on NTHI Stock According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral. The score is primarily constrained by very weak financial performance (large losses, accelerating cash burn, and negative equity) and a bearish technical trend (below key moving averages with negative MACD). Corporate events provide some offset via financing, insider buying, and clinical progress, but valuation remains unattractive given ongoing losses and no dividend support. To see Spark’s full report on NTHI stock, click here. More about NeOnc Technologies Holdings, Inc. YTD Price Performance: -50.91% Average Trading Volume: 51,014 Technical Sentiment Signal: Strong Sell Current Market Cap: $101.1M</div>

NTHI

SBIO

LABU

NeOnc Technologies Holdings, Inc. (NTHI) President Amir F. Heshmatpour purchased 10,000 shares worth $41,500 on May 4, 2026, indicating confidence in the company's future. Analysts have mixed views on NTHI, citing risks from capital-raising efforts and weak financial performance, while noting potential from clinical advancements. The stock has a YTD performance of -50.91% and a market cap of $101.1M, with a neutral rating from TipRanks' AI Analyst due to ongoing losses and negative equity.

Tip Ranks

Neonc Tech

SPDR S&P Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

NeOnc Technologies President Makes Bold Insider Move Signaling Growing Confidence